文献速递肝病消化道肿瘤与早癌

美国非酒精性脂肪性肝病相关肝细胞癌的临床特征与结局

Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-03-17

基于2011至2015年SEER-Medicare数据库的5098例肝细胞癌患者队列,非酒精性脂肪性肝病(NAFLD)是首要病因,占1813例(35.6%)。与丙型肝炎相关肝细胞癌相比,NAFLD与较低的监测接受率、较低的早期肿瘤检出率及略差的总体生存相关。

要点

  • NAFLD是Medicare受益者中肝细胞癌的首要病因,占35.6%。
  • NAFLD相关肝细胞癌的监测接受率和早期检出率均低于丙型肝炎相关肝细胞癌。
  • NAFLD相关肝细胞癌的总体生存略差于丙型肝炎相关肝细胞癌。

核心结论

  • NAFLD是Medicare受益者中肝细胞癌的首要病因。
  • 与其他病因相比,NAFLD与较低的肝细胞癌监测接受率、较低的早期检出率及略差的生存相关。
  • 需要多方面干预以提高监测接受率,从而改善NAFLD相关肝细胞癌患者的预后。

研究设计与样本

  • 基于2011至2015年监测、流行病学和最终结果(SEER)-Medicare数据库的肝细胞癌患者队列研究。
  • 共纳入5098例肝细胞癌患者。
  • 使用多变量logistic回归分析与监测接受、早期肿瘤检出及治愈性治疗相关的因素,使用Cox回归分析与总体生存相关的因素。

主要发现

  • 在5098例肝细胞癌患者中,NAFLD是首要病因,占1813例(35.6%)。
  • 与丙型肝炎相关肝细胞癌相比,NAFLD与较低的监测接受率相关(调整比值比0.22;95%置信区间0.17-0.28)。
  • 与丙型肝炎相关肝细胞癌相比,NAFLD与较低的早期肝细胞癌检出率相关(调整比值比0.49;95%置信区间0.40-0.60)。
  • 与丙型肝炎相关肝细胞癌相比,NAFLD与略差的总体生存相关(调整风险比1.20;95%置信区间1.09-1.32)。
  • NAFLD亚组分析显示,早期肝细胞癌、无腹水/肝性脑病、接受监测及接受治愈性治疗与改善的总体生存相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The extent to which nonalcoholic fatty liver disease (NAFLD) contributes to hepatocellular carcinoma (HCC) prevalence in contemporary practices and whether there are any etiologic differences in surveillance receipt, tumor stage, and overall survival (OS) remain unclear. We aimed to estimate the burden of NAFLD-related HCC and magnitude of associations with surveillance receipt, clinical presentation, and outcomes in a contemporary HCC cohort. METHODS: In a cohort of HCC patients from the Surveillance, Epidemiology and End Results-Medicare database between 2011 and 2015, we used multivariable logistic regression to identify factors associated with surveillance receipt, early-stage tumor detection, and curative treatment. Cox regression was used to identify factors associated with OS. RESULTS: Among 5098 HCC patients, NAFLD was the leading etiology, accounting for 1813 cases (35.6%). Compared with those with hepatitis C-related HCC, NAFLD was associated with lower HCC surveillance receipt (adjusted odds ratio, 0.22; 95% confidence interval [CI], 0.17-0.28), lower early-stage HCC detection (adjusted odds ratio, 0.49; 95% CI, 0.40-0.60), and modestly worse OS (adjusted hazard ratio, 1.20; 95% CI, 1.09-1.32). NAFLD subgroup analysis showed that early-stage HCC, absence of ascites/hepatic encephalopathy, surveillance, and curative treatment receipt were associated with improved OS. NAFLD patients with coexisting liver disease were more likely to have surveillance, early-stage detection, curative treatment, and improved OS than NAFLD patients without coexisting liver diseases. CONCLUSIONS: NAFLD is the leading etiology of HCC among Medicare beneficiaries. Compared with other etiologies, NAFLD was associated with lower HCC surveillance receipt, early-stage detection, and modestly poorer survival. Multifaceted interventions for improving surveillance uptake are needed to improve prognosis of patients with NAFLD-related HCC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Karim MA, Singal AG, Kum HC, et al. Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2022. PMID: 35307595. doi:10.1016/j.cgh.2022.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。